ANGO News and Press, AngioDynamics Inc. From 04/03/24

ANGO - AngioDynamics Q3 2024 Earnings Preview

2024-04-03 13:47:44 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics settles all...

ANGO - AngioDynamics settles all patent litigation with C.R. Bard

2024-04-01 17:30:31 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics divests PIC...

ANGO - AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement...

ANGO - AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results...

ANGO - AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Jim Clemmer, President and Chief...

ANGO - AngioDynamics divests PICC, Midline product portfolio

2024-02-16 16:30:40 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics reports mix...

ANGO - AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million

Portfolio optimization enhances strategic focus and follows initiative to restructure manufacturing footprint Company to discontinue sales of radiofrequency ablation and Syntrax products AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focuse...

ANGO - AngioDynamics gets FDA clearance for Auryon XL catheter

2024-01-23 10:16:28 ET More on AngioDynamics AngioDynamics: Restructuring Initiative May Not Go Far Enough AngioDynamics, Inc. (ANGO) Q2 2024 Earnings Call Transcript AngioDynamics, Inc. 2024 Q2 - Results - Earnings Call Presentation AngioDynamics reports mix...

ANGO - AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease

225-cm Catheter Length Expands Access Points in Atherectomy Procedures to Help Reduce Access Site Complications and Accelerate Patient Recovery AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body&#...

ANGO - AngioDynamics: Restructuring Initiative May Not Go Far Enough

2024-01-14 14:04:11 ET Summary AngioDynamics' latest quarter earnings missed expectations. The company is facing weaker-than-anticipated sales following the rollout of new products forcing management to revise lower full-year guidance. We expect shares to remain volatile until...

Company Name:	AngioDynamics Inc.
Stock Symbol:	ANGO
Market:	NASDAQ
Website:	angiodynamics.com